I watched the webinar with the KOL and came to the conclusion that Bionomics is massive undervalued. This stock could be a tenbeggar! We will see top line data from the SAD P2 fast track trial at end of december and final data from p2b trial in PTSD in June 2023. This trial has also fast track design. Have a look at the presentation on the website of Bionomics
